Notable
NKT3964 · Advanced/Metastatic Solid Tumors
Enrollment increased: 150 → 238 participants
Also in this update: Interventions modified; Trial arms changed: 2 → 10
NiKang Therapeutics, Inc.Phase 1 NCT06586957 Registry history of NCT06586957 on ClinicalTrials.gov (opens the registry)